Cigna Group inc. (NYSE: CI) shares are rebounding Friday after dropping on Thursday following a fourth-quarter earnings miss.

The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.

CEO David Cordani suggested Thursday that the moves are a direct response to the slaying of UnitedHealthcare CEO Brian Thompson and the public outcry over the state of health care. Other news is on ...

Q4 2024 Earnings Call Transcript January 30, 2025 Cigna Corporation misses on earnings expectations. Reported EPS is $6.64 ...

Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The ...

Truist Financial analyst David S Macdonald reiterated a Buy rating on Cigna (CI – Research Report) today. The company’s shares closed yesterday ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Cigna Group closed 23.69% below its 52-week high of $370.83, which the company reached on September 16th.

Cigna Healthcare and Providence are expanding their Los Angeles County network, offering customers several additional care ...

Cigna Group closed 17.56% short of its 52-week high of $370.83, which the company reached on September 16th.